Trial Profile
A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab for Patients With Resected Stages IIIC/IV Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab; Montanide ISA-51; Subunit vaccines
- Indications Malignant melanoma
- Focus Therapeutic Use
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 17 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 04 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.